分享好友 资讯首页 频道列表

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

2026-02-13 09:4013380

Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra across nine diverse patient profiles and journeys, over two years1
Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin2-6
The campaign captures the patients’ clinical and emotional experiences – including before & after treatment imagery – highlighting Sculptra’s adaptability and reinforcing its role in tailored, science-backed regenerative aesthetic care1

ZUG, Switzerland -- (BUSINESS WIRE) --

Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211375008/en/

Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.2-6 With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.2,3,7-14

 

“What excites me about this unique program is how it aims to capture the nuance of clinical practice: different protocols, different goals, and different outcomes, all unified by a science-first approach to aesthetic personalization. And beyond the science, we also notice an emotional journey – seeing patients regain confidence, feel more like themselves, and experience a deeper sense of wellbeing as their natural beauty is restored over time."

 

MS. PRIYANKA CHADHA, FRCS (PLAST)
CONSULTANT PLASTIC SURGEON, GLOBAL EDUCATOR

AMER CLINIC, LONDON

 

Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients – who were all new to injectable aesthetics – over two years, offering a long-term view of how Sculptra performs over time.1 Its launch captures the patients’ personal reflections, results, and before & after treatment imagery, offering a powerful lens into both clinical outcomes and emotional impact.1

The campaign highlights the rich diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.1 Grounded in Galderma’s AART™ (Assessment, Anatomy, Range, and Treatment) methodologies and HIT™ (Holistic Individualised Treatment) protocols, it demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.1

Whether renewing natural volume, improving skin quality, or repositioning tissue for a lifted appearance, each case will highlight Sculptra’s adaptability across diverse indications and patient needs.1 As well its natural, long-lasting clinical outcomes, the campaign captures the emotional resonance of treatment, with improved confidence, self-recognition, and wellbeing seen throughout the group, while also leaving them with a positive first impression of aesthetic treatments.1

 

“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life. This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.”

 

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE CENTER FOR INNOVATION

 

Learn more about We Are All Sculptra here.

About Sculptra

Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide progressive and sustained regenerative effect across all three skin layers.2-6 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.2,15-18 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.8-11 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.2,17,19,20

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. We Are All Sculptra. 2025

1.

 

2.

 

U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed December 2025.

3.

 

Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042.

4.

 

Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France.

5.

 

Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.

6.

 

Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417.

7.

 

Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France.

8.

 

Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States.

9.

 

Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States.

10.

 

Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229.

11.

 

Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.

12.

 

Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010;62(3):448–62. doi: 10.1016/j.jaad.2009.07.040.

13.

 

Galderma. Data on File (MA-47133).

14.

 

Mu X, et al. 12-Month Effectiveness and Safety of PLLA Treatment of Midface in Chinese Subjects: A Multicenter, Randomized, No-Treatment Controlled Study. Presented at AMWC. March 30 to April 1, 2023. Monte-Carlo, Monaco.

15.

 

Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755.

16.

 

Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x.

17.

 

Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–922. doi: 10.1111/dsu.12164.

18.

 

Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239.

19.

 

Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015.

20.

 

Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC. March 30 - April 1, 2023. Monte-Carlo, Monaco.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260211375008/en/

CONTACT:

For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com

 

反对 0
举报 0
收藏 0
打赏 0
评论 0
Hytera Wins Two ICCA Awards and Showcases AI-Powered Innovations at CCW 2026
LONDON--(BUSINESS WIRE)--Hytera, a leading global provider of critical communications technologies and solutions, concluded a successful participation at Critical Communications World (CCW) 2026 in London, showcasing its latest AI powered and missi...

0评论2026-06-221357

NIQ推出NIQ Cadence:一款提升行銷效果的複合型AI作業系統
NIQ Cadence整合了全球資料、模型和知識,協助行銷人員以更快的速度、更深入的智能,大規模地將洞察轉化為實際影響力。 芝加哥--(BUSINESS WIRE)--(美國商業資訊)-- 消費者情報領域的全球領導者NIQ (NYSE: NIQ) 今日推出NIQ Cadence,這款複合型AI作業系統旨在變革企業衡量行銷成效、完善預算以及根據資料採取行動的方式。NIQ Cadence將資料和情報整合到一個連續的環境中,使行銷人員擺脫分散的報告,轉而使用單一系統來賦能決策...

0评论2026-06-221799

One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street
New Zealand’s leading digital services and connectivity provider partners with Rimini Street to stabilize mission-critical Oracle systems, solve complex interoperability challenges and fund AI transformation LAS VEGAS--(BUSINESS WIRE)--Rimini Street...

0评论2026-06-221407

IQM 与 Real Asset Acquisition Corp. 联合举办首届资本市场日活动,向投资者及分析师展示未来发展战略
活动演示内容现已开放回看,全面介绍 IQM 的增长战略、技术发展路线图、商业化进展以及对量子计算未来发展的愿景。 美国新泽西州普林斯顿和芬兰埃斯波--(美国商业资讯)--全球领先的全栈超导量子计算机企业 IQM Quantum Computers Oy(原名 IQM Finland Oy,以下简称“IQM”、“IQM Quantum Computers”或“公司”) 今日宣布,公司资本市场日活动的演示资料现已上线IQM投资...

0评论2026-06-221361

Andersen Global携手JMP Advisors进一步强化在印度的业务布局
旧金山--(美国商业资讯)-- Andersen Global与印度的JMP Advisors达成合作协议,在现有法律服务能力的基础上,为其在印度的业务增添了税务服务能力。 JMP Advisors致力于在税务、监管和交易事务方面提供专业咨询,服务于在复杂且不断演变的商业环境中运营的本土及跨国客户。该公司提供的服务涵盖国际与印度国内税务、转让定价、跨境架构设计、外商投资咨询、交易支持、继任规划及监管事务。其客户群体包括跨国公司、成长型企业、私募股权及风险资本支持的企业,以及高净值个人与家...

0评论2026-06-221798

Moody’s為各大AI平台推出決策級AI技能
今日率先登陸Microsoft 365 Copilot Cowork,並將逐步擴充至其他相容的AI平台 紐約--(美國商業資訊)-- Moody’s Corporation (NYSE: MCO)今日宣布推出其首批AI技能——這是一套專門設計的與平台無關的指令工具套件,旨在將Moody’s的分析架構進行編碼,並將AI代理與其決策級智慧相連結。這些Moody’s技能將率先在Microsoft 365 Copilot Cowork等相容的...

0评论2026-06-221051

Joe Vernachio被任命为SOREL总裁
波特兰市,俄勒冈州--(美国商业资讯)-- Columbia Sportswear Company(Nasdaq:COLM)是户外运动服饰、鞋类、配饰及装备领域的领先创新企业。该公司今日宣布Joe Vernachio将出任SOREL下一任总裁。SOREL创立于1962年,是功能性与生活方式鞋类领域的领导者,其产品涵盖从苔原到纽约市街头的各种环境。 首席执行官兼董事会主席Tim Boyle表示:“我们非常高兴欢迎Joe Vernachio重返Columbia Sportswea...

0评论2026-06-221646

Kinaxis公布年度及特别股东大会的投票结果
渥太华,安大略省--(美国商业资讯)--端到端供应链规划与协调领域的全球领导者Kinaxis®Inc.(以下简称“Kinaxis”或“公司”) (TSX:KXS)在今日召开的年度及特别股东大会(以下简称“大会”)上提交给股东的所有决议均已获得批准,具体详情载于公司2026年5月5日发布的管理层信息通告(以下简称“通告”)中。 1. 董事选举 股东投票选举了提名加入Kinaxis董事...

0评论2026-06-221636

TestMu AI 正式发布 n8n 合作伙伴集成方案,将真实浏览器基础设施引入 AI 智能体工作流
开发者现可直接在 n8n 工作流中调用 TestMu AI Browser Cloud,使 AI 智能体能够在超过 3,000 种浏览器与操作系统环境中运行 美国旧金山和印度诺伊达--(美国商业资讯)--全球首个全栈智能体 AI 质量工程平台 TestMu AI(前身为 LambdaTest)今日宣布,正式推出其面向 n8n 的 TestMu AI Agent 官方合作伙伴集成方案。n8n 是 AI 智能体及企业自动化领域增长最快的工作流自动化平台之一。 作为 n8n 官方认证并建立合作关...

0评论2026-06-221981

Omdia:受存储器市场打破历史规律推动, 2026年第一季度,半导体市场营收突破3000亿美元
伦敦--(美国商业资讯)--在半导体行业创下历史新高的一年之后,新年伊始依然延续了强劲的增长势头。根据Omdia的最新研究,2026年第一季度的半导体营收较2025年第四季度环比增长27%,达到3190亿美元。存储器营收是推动这一增长的主要动力,其在2026年第一季度的环比增幅超过80%。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260610763749/zh-CN/ 自Omdia于2002年第一季度...

0评论2026-06-221902